Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency
- 1 September 2021
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , 538-548
Abstract
Background Dysbetalipoproteinemia (DBL) is characterized by the accumulation of remnant lipoprotein particles and associated with an increased risk of cardiovascular and peripheral vascular disease (PVD). DBL is thought to be mainly caused by the presence of an E2/E2 genotype of the apolipoprotein E (APOE) gene, in addition to environmental factors. However, there exists considerable variability in the phenotype of these patients. Objective The objectives were to verify the proportion of DBL subjects diagnosed using the gold standard Fredrickson criteria who did not carry E2/E2 and to compare the clinical characteristics of DBL patients with vs without E2/E2. Methods A total of 12 432 patients with lipoprotein ultracentrifugation as well as APOE genotype or apoE phenotype data were included in the present retrospective study. Results Among the 12 432 patients, 4% (n=524) were positive for Fredrickson criteria (F+), and only 38% (n=197) of the F+ individuals were E2/E2. The F+ E2/E2 group had significantly higher remnant cholesterol concentration (3.44 vs 1.89 mmol/L) and had higher frequency of DBL-related xanthomas (24% vs 2%) and floating beta (95% vs 11%) than the F+ non-E2/E2 group (p<0.0001). The F+ E2/E2 group had an independent higher risk of PVD (OR 11.12 (95% CI 1.87-66.05) p=0.008) events compared to the F+ non-E2/E2 group. Conclusion In the largest cohort of DBL worldwide, we demonstrated that the presence of E2/E2 was associated with a more severe DBL phenotype. We suggest that two dysbetalipoproteinemia phenotypes should be distinguished: the multifactorial remnant cholesterol disease and the genetic apoE deficiency disease.Keywords
This publication has 26 references indexed in Scilit:
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Non-HDL-cholesterol/apolipoprotein B ratio: A useful distinguishing feature in the screening for type III hyperlipoproteinemiaJournal of Clinical Lipidology, 2010
- Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case–control studyAtherosclerosis, 2009
- A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemiasNature Clinical Practice Endocrinology & Metabolism, 2008
- Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein BJournal of Clinical Lipidology, 2007
- Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B ConcentrationsClinical Chemistry, 2005
- Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery diseaseJACC, 2005
- Apolipoprotein E: Far More Than a Lipid Transport ProteinAnnual Review of Genomics and Human Genetics, 2000
- Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (APO E‐III) in the very‐low‐density lipoproteinsFEBS Letters, 1975
- Type III Hyperlipoproteinemia: An Analysis of Two Contemporary DefinitionsAnnals of Internal Medicine, 1975